The EMA has validated the Marketing Authorization Application (MAA) for a vaccine developed in collaboration between Valneva and Pfizer.
6 reports, 3 independent
Updated Sep 15
Gone quiet
Reached 4 outlets in its first 24 hours
- Reports
- 6
- Developments
- 3
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The EMA has validated the Marketing Authorization Application (MAA) for a vaccine developed in collaboration between Valneva and Pfizer.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.EMA is reviewing the vaccine application, and Pfizer has secured exclusive commercialization rights.1 source
- Pfizer and Valneva are co-developing a vaccine and planning regulatory submissions to authorities.Sub-event
EMA validates MAA for Pfizer/Valneva collaborative vaccine.1 source
Keep exploring
The entities involved
-
Valneva SE
French vaccine producer
Nothing else this week.
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
-
European Medicines Agency
highest regulatory authority on medicines in the European Union